A&B and China Medical System enter agreement with Faron for Traumakine

20 May 2015

Clinical-stage biopharma company Faron Pharmaceuticals has entered into strategic agreements with China Medical System Holding and A&B Ltd to develop and commercialize Traumakine (interferon beta-1a) to treat moderate to severe acute respiratory distress syndrome.

China Medical System has acquired exclusive assets and rights for the development and commercialization of Traumakine in China, Hong Kong, Macao and Taiwan. A&B, an investment and development company based in Hong Kong, owned by the chief executive of China Medical System, has made a simultaneous strategic $5.6 million investment in Faron.

This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Try before you buy

Free

7 day trial access

Take a Free Trial

All the news that moves the needle in pharma and biotech
Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
Receive The Pharma Letter daily news bulletin, free forever.

Become a subscriber

£820

Or £77 per month

Subscribe Now

Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
Daily roundup of key events in pharma and biotech.
Monthly in-depth briefings on Boardroom appointments and M&A news.
Choose from a cost-effective annual package or a flexible monthly subscription

The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK